Alk-Abello AS (AKBLF)
24.60
0.00 (0.00%)
USD |
OTCM |
Sep 18, 16:00
Alk-Abello Enterprise Value: 5.412B for Sept. 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2024 | 5.412B |
| September 17, 2024 | 5.412B |
| September 16, 2024 | 5.412B |
| September 13, 2024 | 5.412B |
| September 12, 2024 | 5.412B |
| September 11, 2024 | 5.412B |
| September 10, 2024 | 5.412B |
| September 09, 2024 | 5.412B |
| September 06, 2024 | 5.412B |
| September 05, 2024 | 5.412B |
| September 04, 2024 | 4.766B |
| September 03, 2024 | 4.766B |
| August 30, 2024 | 4.766B |
| August 29, 2024 | 4.766B |
| August 28, 2024 | 4.766B |
| August 27, 2024 | 4.766B |
| August 26, 2024 | 4.766B |
| August 23, 2024 | 4.766B |
| August 22, 2024 | 4.766B |
| August 21, 2024 | 4.766B |
| August 20, 2024 | 4.766B |
| August 19, 2024 | 4.766B |
| August 16, 2024 | 4.766B |
| August 15, 2024 | 4.766B |
| August 14, 2024 | 4.766B |
| Date | Value |
|---|---|
| August 13, 2024 | 4.766B |
| August 12, 2024 | 4.766B |
| August 09, 2024 | 4.766B |
| August 08, 2024 | 4.766B |
| August 07, 2024 | 4.766B |
| August 06, 2024 | 4.766B |
| August 05, 2024 | 4.766B |
| August 02, 2024 | 4.766B |
| August 01, 2024 | 4.766B |
| July 31, 2024 | 4.766B |
| July 30, 2024 | 4.766B |
| July 29, 2024 | 4.766B |
| July 26, 2024 | 4.766B |
| July 25, 2024 | 4.837B |
| July 24, 2024 | 4.837B |
| July 23, 2024 | 4.837B |
| July 22, 2024 | 4.837B |
| July 19, 2024 | 4.837B |
| July 18, 2024 | 4.837B |
| July 17, 2024 | 4.837B |
| July 16, 2024 | 4.837B |
| July 15, 2024 | 4.837B |
| July 12, 2024 | 4.837B |
| July 11, 2024 | 4.837B |
| July 10, 2024 | 4.837B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.967B
Minimum
Jul 07 2023
5.672B
Maximum
Dec 27 2021
3.649B
Average
3.599B
Median
Sep 16 2022
Enterprise Value Benchmarks
| Genmab AS | 14.38B |
| Ascendis Pharma AS | 8.983B |
| Galecto Inc | -7.962M |
| Evaxion Biotech AS | 17.82M |
| IO Biotech Inc | -25.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 29.01M |
| Revenue (Quarterly) | 198.33M |
| Total Expenses (Quarterly) | 160.22M |
| EPS Diluted (Quarterly) | 0.1299 |
| Gross Profit Margin (Quarterly) | 63.10% |
| Profit Margin (Quarterly) | 14.63% |
| Earnings Yield | 1.83% |
| Operating Earnings Yield | 2.40% |
| Normalized Earnings Yield | 1.828 |